LA VAPOR INC. – FDA Warning Letter, Aug 22, 2025

The U.S. Food and Drug Administration (FDA) issued a Warning Letter to LA VAPOR INC, located at 8725 Golden Spike Lane, Houston, TX, on August 21, 2025. The letter follows an inspection by the FDA"s Center for Tobacco Products, which identified that LA VAPOR INC sells and distributes e-liquid products in the United States without the necessary premarket authorization. These products fall under the regulatory framework of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as amended by the Consolidated Appropriations Act, 2022, which extends FDA"s jurisdiction to all products containing nicotine from any source.

The main violation cited is the marketing of "Hi Drip Nectarine Lychee 6MG 100ML," a new tobacco product lacking the required FDA marketing authorization order. As it was not commercially available in the U.S. before February 15, 2007, the product is deemed adulterated and misbranded under sections 902(6)(A) and 903(a)(6) of the FD&C Act, respectively.

The FDA requires LA VAPOR INC to take immediate corrective actions to comply with the FD&C Act. This includes ceasing the sale and distribution of unauthorized products and submitting a written response within 15 working days detailing the steps taken to rectify these violations. Failure to comply may result in enforcement actions, including civil penalties, seizure, or injunction. The company is advised to ensure all products and related marketing comply with applicable regulations to avoid further violations.